Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Organisation › Details

Editas Medicine Inc. (Nasdaq: EDIT)

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. *


Period Start 2013-11-25 established
Products Industry CRISPR gene editing technology
  Industry 2 TALEN® technology (Transcription Activator-Like Effector Nuclease)
Region Region Cambridge, MA
  Country United States (USA)
  Street 11 Hurley Street
  City 02141 Cambridge, MA
  Tel +1-617-401-9000
    Address record changed: 2020-12-02
Basic data Employees n. a.
  Currency USD
  Annual sales 20,531,000 (revenues, consolidated (2019) 2019-12-31)
  Profit -133,746,000 (2019-12-31)
  Cash 415,000,000 (2020-03-31)
    * Document for �About Section�: Editas Medicine, Inc.. (1/21/19). "Press Release: Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10)". Cambridge, MA.
Record changed: 2020-07-26


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Editas Medicine Inc. (Nasdaq: EDIT)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px

» top